asc41
Metabolic Dysfunction-Associated Steatotic Liver Disease
Explore 131 assets in Metabolic Dysfunction-Associated Steatotic Liver Disease →Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Gannex Pharma Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05462353CT.gov Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH | — | Active Not Recruiting | — | — | — |
NCT04845646CT.gov DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD. | — | Completed | — | — | — |
NCT04692025CT.gov Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers | — | Completed | — | — | — |
NCT04686994CT.gov Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metabolic Dysfunction-Associated Steatotic Liver Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| asc41 (this asset) | Gannex Pharma Co., Ltd. | P2 | B · 58 |
| Dapagliflozin | Post Graduate Institute of Medical Education and Research, Chandigarh | P4 | BBB |
| Exenatide | Fudan University | P4 | BBB |
| Metformin | Xiqiao Zhou | P4 | BBB |
| Empagliflozin | Justin Ryder | P4 | BBB |
| Pioglitazone | Badr University | P4 | BBB |
| Tirzepatide | Regeneron Pharmaceuticals | P3 | BBB |
| Saroglitazar | Zydus Lifesciences Limited | P4 | BB |
| Clesacostat | Columbia University | P2 | BB |
+42 more in the Metabolic Dysfunction-Associated Steatotic Liver Disease cohort
Other indications for asc41
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatohepatitis | — | P2 | CCC · 53 |
| Hyperlipidemia | — | P1 | CCC · 52 |
| Obesity Disorder | — | P1 | CC · 44 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. asc41 in Metabolic Dysfunction-Associated Steatotic Liver Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/asc41-metabolic-dysfunction-associated-steatotic-liver-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →